COST-EFFECTIVENESS OF ADALIMUMAB IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (SUB-ACUTE) IN THE UK
Hongbo Yang 1
Alistair Curry 2
Song Wang 3
MIn A. Yang 1
Martha Skup 3
Jingdong Chao 3
Yanjun Bao 3
1 Analysis Group, Inc., Boston, United States
2 Abbvie Ltd, Berkshire, United Kingdom
3 Abbvie Inc., North Chicago, United States
Conference
UEG Week 2014
Citation
United European Gastroenterology Journal; 2014: 2 (Supplement 1)
Login to access library content
Do you need help setting up your myUEG account?
Contact us at office@ueg.eu